The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

CCR2 was highly expressed on malignant monocytes from AML patient samples, with cases of acute monocytic leukemia (M5) and acute myelomonocytic leukemia (M4), showing the highest levels of expression.